I have a flow system

Chapter 229 "Rapid Detection Technology Based on CRISPR"

Since May, Wu Zhou's Aiying Medical has begun to produce results, for example, related equipment for testing viruses.

It was originally a special research and development project by the company for the research project of the virus purifier, but it did not expect the surprise of unexpected derivatives.

"A rapid detection technology based on CRISPR."

The team led by Dr. Zhang, "Aiying Medical and Aiying Biological Gene Editing Master", found that CRISPR_Cas9 can specifically cut DNA under the guidance of gRNA and realize the gene editing function, so as to quickly detect genes (Cas13, Cas12a, Csm6), related articles have been published in Nature and Science.

Compared with traditional molecular diagnostic technologies such as pcr and ngs, CRISPR detection technology is more sensitive, anti-interference, more accurate and more convenient to use.

Traditional PCR requires dozens of copies of the virus to detect, while the CRISPR detection technology only needs 1-3 copies of the unit.

Dozens of times more sensitive.

And it is more convenient in the use scene, no need for large instruments, no laboratory, and it can be used at home. "

so.
As a result, after receiving a large number of clinical trial results to verify, Huaxia gave an accelerated approval process.

If things go well, production should start at the end of May or early June. Aiying Medical is already working on the related production lines, and all the existing production lines can be adjusted.

This important news was published in relevant authoritative journals in mid-May. As the temperature of masks is raging around the world, countless people have noticed its harm. During this time, related technologies, articles, and Top journals such as sci and nature are particularly easy, and the publishing speed is fast.

The emergence of this technology has attracted great attention from the global medical industry, because its various data are ahead of other similar detection technologies.

Dr. Zhang became famous for a while.

There was also an endless stream of domestic and foreign media interviews.

"This technology can be implemented so quickly, not all because of me, but also with the help of my team members and other colleagues in the company. Without their help, it would be impossible to get the results so quickly." Dr. Zhang But he said with a serious face.

He was telling the truth.

Because the entire research and development process, even in retrospect now, was beyond his expectation.

Encountered a little problem, or other team members in the group suddenly gave the right direction with a flash of spirit.

Or other groups in the company happen to have experts in related fields who can help solve the problem.

In addition, members of the team have super executive power.

Unprecedented comfort, I seem to only provide a general direction, ideas, and then the specific landing process, it seems that I don't need to worry about it.

He was very fortunate at the moment, and he agreed to the headhunting company's invitation in a fit of anger.

But Dr. Zhang told the truth, the audience who saw the interview.

But I feel that Dr. Zhang is being humble.

"Humble gentleman."

"This is what our Chinese scientists really should look like."

"Wu Zhou's luck is also very good. He just entered the medical field and won a big cow. The point is that he has achieved results."

"This thing is useful when researched, but it is gone in the country. Only one or two pop up occasionally."

"Are you in the valley? Look at the international news. There are millions of people added every day in foreign countries. I don't know how many people are actually there."

"Hehe, so what, foreign technology is much more advanced than ours in China."

At the same time, many domestic and foreign medical institutions who are interested in this technology are also following up to verify the feasibility of this technical route.

After all, the current global nucleic acid program is very uncomfortable, because the number of viruses required is much higher, so it is necessary to poke the nose and eyes severely, which makes many people feel disgusted and even resisted psychologically.

But if this ultra-sensitive technology is used, the nucleic acid experience will be much better.

The second is timeliness. The current nucleic acid solutions generally take more than 6 hours to produce results.

The timeliness of Dr. Zhang's plan only takes about half an hour, and there is even room for further improvement.

In addition, the accuracy is high, the detection is convenient, and the cost is not high.

Taken together, the results are obvious.

After the internal laboratory verified that it was correct, the person in charge of the relevant pharmaceutical group began to contact Wu Zhou Company, hoping to obtain the authorization of this patented technology.

Wu Zhou has full confidence in this technology. The result given by the system is the best technology at the moment, and it is the best in almost every aspect.Even if the technology is announced now, it will take at least several months for other related companies at home and abroad to follow up the research and development of related technologies as soon as possible, but this is based on the premise of similar routes.

As for the technology patent, Wu Zhou has asked the company's lawyers to apply for patents in major global markets. The company is also studying some related technical routes, and some progress has been made.

Moreover, the patent can not only be applied for after the finished product is completed, but also the technology can be divided into many small technologies.

What is certain is that it is very difficult to circumvent Wu Zhou's patents, and there is no way to achieve results in the short term.

On May 5th, the first American company hoped to cooperate, and gave 19 million US dollars, hoping to obtain global authorization, but Wu Zhou didn't even respond.

On May 5, three more companies contacted, and Wu Zhou only contacted one of them. It’s not that this company is big, but because this company has a good drug, and Wu Zhou wants to get the authorization.
As the internal verification results of each company are released one after another, more and more companies have contacted Aiying Group.

On May 5, after a round of screening by the Aiying Group, they invited the heads of 31 pharmaceutical companies in China to gather in Yuncheng.

In a quiet conference room, an 8-meter-long wooden conference table is placed in the middle of the room. A white door that opens inward separates the room from the outside world. There is a thick white floor tile, and the sunlight through the window makes the whole room look extraordinarily bright.

Wu Zhou sat at the main seat, surrounded by the company's technical staff, legal affairs, and business negotiators, and on the other side were representatives of other related pharmaceutical companies. There were Chinese and white people. The two sides were sitting face to face at the moment, and the atmosphere was tense. And looking forward to it.

"First of all, I would like to thank you all for coming. As a newly established biomedical company, I would like to thank you for your attention and recognition of our company's related technologies." Wu Zhou said with a smile.

"Mr. Wu is polite. We are still the most powerful company in the field of biomedicine. Whether it is established early or late does not mean that the company is strong or weak. We also admire Mr. Wu's large investment in the field of biomedicine. In the future, I believe There will be more cooperation opportunities with Mr. Wu's company." Someone said with a smile.

The project has not been discussed yet, so of course Wu Zhou was coaxed to talk about it.

"However, we have heard about Mr. Wu's achievements in the food field before we came here. The food of Qiao Fei's family is indeed very good. I believe that the future Aiying medical related products will definitely be able to compete with Mr. Wu. Under the leadership of the company, we will make better products and benefit countless patients."

After a bunch of flattering opening remarks, formal business negotiations followed.

"This technology, I believe that everyone who is doing it must have understood it before coming here. This is the most advanced technology at the moment, and it is not one of them." Wu Zhou said confidently.

"Mr. Wu, your company is indeed leading in the application of this technology this time, but I think Mr. Wu must also know that CRISPR-related companies and teams, we in the United States were the first to start research and are technology pioneers in this industry. "A white man in a suit said seriously to Wu Zhou that the price was negotiated.

Rare things are expensive, as long as the opponents feel that their things are not rare enough, then the price is of course out of the question.

"Gunpowder was first invented by us in China, but after a while, you used it better than us, didn't you?" Wu Zhou responded with a smile.

Although this technology is as he said, the United States is more advanced, and it has even been applied to the clinical stage.

But this time, Dr. Zhang's team has developed a new type of gene editing tool based on this technology, which has stronger accuracy, specificity and wider application range.

Wu Zhou's gesture of confidence at this moment made the person in charge of a pharmaceutical company on the opposite side look at each other in blank dismay.

They couldn't tell whether Wu Zhou was pretending on purpose, or whether he really knew about the progress of foreign research.

But Wu Zhou no longer intends to chat with them.

It's time to get down to business. The purpose of these people is to obtain the global authorization of this technology. After expressing their ideas, they will directly offer quotations.

"Mr. Wu, our company invested 3000 million US dollars, which is the highest price I can get." It was the white person in charge of the pharmaceutical company just now.

Wu Zhou glanced at him. "That's really a pity. It seems that we have no chance to cooperate with your company."

When other people saw this scene, the price also rose sharply.

As more and more people bid, and more and more competitors, the price began to rise.

1 million, 3 million US dollars, 5 million US dollars, the highest even reached 15 billion US dollars.It's like an auction market.

"It's too high, are you crazy?" The person in charge of the pharmaceutical company who quoted 3000 million couldn't help but criticize while looking at the others around him.

Although this technology is the most advanced at the moment, it is at least for the moment. As long as someone updates the technology in the future and it is better than the technology, then the patent licensing fee will be in vain.

Besides, the mask looks very serious now, but it may not be so serious for a long time in the future. It is crazy to spend 15 billion US dollars to buy an uncertainty.

"Thank you for your recognition of our company's technology. The application process of new technology will inevitably bring risks, such as being replaced by more advanced technology. Our company will not do this kind of thing that puts all the risks on the partners."

"Although making money is very important, it doesn't matter to me if there is more or less money. My original intention to enter the medical field is to make good products and benefit ordinary people."

"This is a related technology for detecting masks. Now everyone is clearly aware of its seriousness. I hope this technology can benefit the general public faster and make a little contribution to preventing its further spread."

After Wu Zhou said a lot.

"So, our company will not consider the buyout authorization for the time being. What I hope is to share the authorization with a ratio of 30%."

"Mr. Wu, some of us" still want to fight for global channel authorization.

But Wu Zhou was firm.

Wu Zhou's plan really moved some people, after all, it can greatly reduce this risk.

"Mr. Wu, 30% is too high. We can only agree to a maximum of 10% of the relevant technical cooperation patent fees. What do you think?"

"Of course there is no problem. I can accept 10%, but there are additional conditions. If this cooperation is established, then our company will only need to pay 10% as an agent of some of your company's products?"

After some negotiations between you and me, it was finally determined that it was 20%.

(End of this chapter)